Kyle Gano

Chief Executive Officer

Kyle Gano (Chief Executive Officer) filed 1 Form 4 report in the trailing twelve months (0 purchases, 1 sale), most often in Neurocrine Biosciences, Inc. (NBIX). The largest single filing was $4.8M of NBIX (36,400 sh across 2 lots, as filed), executed Jan 16.

Add to watchlist

Return, ttmiAverage return per filing, trailing twelve months

–

no purchases on file

Delay-adjustediThe same average, entered at disclosure dates

–

returns measure stock purchases only

Filings, ttm

0 buys · 1 sells

Median delay

–

execution → disclosure

Volume, ttmiDollar value disclosed in the trailing twelve months

$4.8M

shares × price, as filed

Last traded

Jan 16

Filed Jan 20

Median ADV $194.2M across their filed names

Open performance→

Volume by month

Buys $0 Sells $14.7M

Shares × price, as filed · by filing month · past 24 months

Sectors filed on

Healthcare 1 filing

Sector per market data · by filing · past 12 months

Most traded names

NBIX Neurocrine Biosciences, Inc. NBIX · 0 buys · 5 sells 5 filings

Recent filings

NBIXSALE Neurocrine Biosciences, Inc. View filing → $4.8M
36,400 sh across 2 lots
Exec Jan 16
Filed Jan 20 · 5:30 PM ET NBIXSALE Neurocrine Biosciences, Inc. View filing → $299K
2,558 sh across 2 lots
Exec Feb 13 2025
Filed Feb 14 2025 · 5:30 PM ET NBIXSALE Neurocrine Biosciences, Inc. View filing → $116K
980 sh × $118.39
Exec Feb 10 2025
Filed Feb 12 2025 · 5:30 PM ET NBIXSALE Neurocrine Biosciences, Inc. View filing → $236K
1,541 sh × $152.87
Exec Jan 31 2025
Filed Feb 4 2025 · 5:30 PM ET NBIXSALE Neurocrine Biosciences, Inc. View filing → $9.2M
65,000 sh across 2 lots
Exec Jan 15 2025
Filed Jan 17 2025 · 5:30 PM ET